Long-term outcomes of allogeneic hematopoietic cell transplantation with intensified myeloablative conditioning for refractory myeloid malignancy

Bone Marrow Transplant. 2016 Jun;51(6):869-71. doi: 10.1038/bmt.2016.15. Epub 2016 Feb 15.

Authors

N Kawashima¹, Y Inamoto², T Sato¹, M Nakashima¹, Y Kagaya¹, K Watakabe¹, A Seto¹, N Fukushima¹, S Kurahashi¹, Y Ozawa¹, K Miyamura¹

Affiliations

¹ Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
² Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.

PMID: 26878661
DOI: 10.1038/bmt.2016.15

No abstract available

MeSH terms

Adult
Disease-Free Survival
Female
HLA Antigens / chemistry
Hematopoietic Stem Cell Transplantation*
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
Leukemia, Myeloid, Acute / therapy*
Male
Middle Aged
Myeloablative Agonists / therapeutic use
Neoplasm Recurrence, Local / drug therapy
Remission Induction
Retrospective Studies
Time Factors
Transplantation Conditioning / methods*
Transplantation, Homologous
Treatment Outcome
Young Adult

Substances

HLA Antigens
Myeloablative Agonists